Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 141
Filter
Add more filters










Publication year range
1.
Biochemistry ; 40(45): 13430-8, 2001 Nov 13.
Article in English | MEDLINE | ID: mdl-11695889

ABSTRACT

In the preceding paper in this issue [Ost, T. W. B., Miles, C. S., Munro, A. W., Murdoch, J., Reid, G. A., and Chapman, S. K. (2001) Biochemistry 40, 13421-13429], we have established that the primary role of the phylogenetically conserved phenylalanine in flavocytochrome P450 BM3 (F393) is to control the thermodynamic properties of the heme iron, so as to optimize electron-transfer both to the iron (from the flavin redox partner) and onto molecular oxygen. In this paper, we report a detailed study of the F393H mutant enzyme, designed to probe the structural, spectroscopic, and metabolic profile of the enzyme in an attempt to identify the factors responsible for causing the changes. The heme domain structure of the F393H mutant has been solved to 2.0 A resolution and demonstrates that the histidine replaces the phenylalanine in almost exactly the same conformation. A solvent water molecule is hydrogen bonded to the histidine, but there appears to be little other gross alteration in the environment of the heme. The F393H mutant displays an identical ferric EPR spectrum to wild-type, implying that the degree of splitting of the iron d orbitals is unaffected by the substitution, however, the overall energy of the d-orbitals have changed relative to each other. Magnetic CD studies show that the near-IR transition, diagnostic of heme ligation state, is red-shifted by 40 nm in F393H relative to wild-type P450 BM3, probably reflecting alteration in the strength of the iron-cysteinate bond. Studies of the catalytic turnover of fatty acid (myristate) confirms NADPH oxidation is tightly coupled to fatty acid oxidation in F393H, with a product profile very similar to wild-type. The results indicate that gross conformational changes do not account for the perturbations in the electronic features of the P450 BM3 heme system and that the structural environment on the proximal side of the P450 heme must be conformationally conserved in order to optimize catalytic function.


Subject(s)
Bacterial Proteins , Cytochrome P-450 Enzyme System/chemistry , Escherichia coli/enzymology , Mixed Function Oxygenases/chemistry , Circular Dichroism , Crystallization , Cytochrome P-450 Enzyme System/genetics , Electron Spin Resonance Spectroscopy , Histidine/genetics , Kinetics , Ligands , Mixed Function Oxygenases/genetics , Models, Molecular , Mutation , NADPH-Ferrihemoprotein Reductase , Phenylalanine/genetics , Protein Conformation , Spectrophotometry, Ultraviolet , Thermodynamics
2.
Biol Pharm Bull ; 24(9): 988-94, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11558582

ABSTRACT

Repetitive administration of propranolol (PL) in rats decreases the activities of cytochrome P450 (CYP) 2D enzyme(s) in hepatic microsomes. We examined the properties of 4-hydroxypropranolol (4-OH-PL) as an inactivator of rat liver microsomal CYP2D enzyme(s) using bunitrolol (BTL) 4-hydroxylation and PL 5- and 7-hydroxylations as indices of CYP2D enzyme activity. Rat microsomal BTL 4-hydroxylase activity was inhibited by the addition of 4-OH-PL to the incubation medium. The inhibition was greater after preincubation of microsomes with 4-OH-PL in the presence of NADPH than in its absence. The type of inhibition kinetics of BTL 4-hydroxylase by 4-OH-PL was changed from a competitive type to a noncompetitive type by the preincubation. The inhibition of rat liver microsomal PL 5- and 7-hydroxylases by 4-OH-PL was blocked efficiently by co-incubation with quinine, a typical inhibitor of rat CYP2D enzyme(s), or to a lesser extent by BTL. However, quinidine, a diastereomer of quinine, did not significantly protect against the enzyme inactivation. The protective capacities of the substrate and inhibitors reflected their affinities for rat CYP2D enzyme(s). BTL hydroxylase was not affected by either 1,4-naphthoquinone or 1,4-dihydroxynaphthalene which are possible metabolites of 4-OH-PL. These results provide further evidence to support the notion that PL is biotransformed by rat CYP2D enzyme(s) to 4-OH-PL, which is further oxidized to a chemically reactive metabolite in the active site. The inactivation of CYP is likely the result of covalent binding of the reactive species to an amino acid residue of the active site.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Enzyme Inhibitors/pharmacology , Propranolol/analogs & derivatives , Propranolol/pharmacology , Adrenergic beta-Antagonists/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Enzyme Inhibitors/pharmacokinetics , Hydroxylation , In Vitro Techniques , Kinetics , Male , Microsomes, Liver/metabolism , NADP/metabolism , Propanolamines/pharmacokinetics , Propranolol/pharmacokinetics , Rats , Rats, Wistar , Substrate Specificity
3.
Synapse ; 39(2): 161-6, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11180503

ABSTRACT

Although the behavioral consequences of methamphetamine (METH) abuse have been extensively documented, a more precise and thorough understanding of underlying neurobiological mechanisms still requires the use of animal models. To study these biochemical processes in experimental animals requires consideration for the broad range of human METH abuse patterns and the many factors that have been identified to profoundly influence the behavioral and neurochemical effects of exposure to METH-like stimulants. One potentially critical issue relates to pharmacokinetic differences between the species. In this review, METH plasma pharmacokinetic profiles after single and multiple dose intravenous METH administration are compared for the rat and human. Significant differences in elimination half-life between the two species (t1/2: rat-70 min, human-12 h) result in markedly dissimilar profiles of METH exposure. However, the plasma profile of a human METH binge pattern can be approximated in the rat by increasing METH dose frequency. Consideration of METH pharmacokinetics in animal models should permit a closer simulation of the temporal profile of METH exposure in the human CNS and should provide further insight into the mechanisms contributing to the addiciton and psychopathology associated with METH abuse.


Subject(s)
Amphetamine-Related Disorders/metabolism , Methamphetamine/pharmacokinetics , Amphetamine/blood , Animals , Disease Models, Animal , Humans , Methamphetamine/blood , Rats
4.
Synapse ; 31(2): 125-33, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10024009

ABSTRACT

We compared the behavioral and caudate-putamen extracellular dopamine responses following intravenous (3.6 mg/kg) and subcutaneous (8 mg/kg) amphetamine administration using 2-min microdialysate sampling intervals, and doses of the drug selected to achieve comparable maximal brain concentrations. Following intravenous amphetamine, dopamine peaked within the first 2 min, then declined with a first-order decay rate of 0.018+/-0.007 min(-1). Following subcutaneous amphetamine, dopamine achieved maximum concentrations at 9 min and remained near peak levels for about 30 min before declining with a first-order decay rate of 0.019+/-0.008 min(-1). Maximal brain amphetamine levels and peak dopamine concentrations were equivalent following either route of drug administration. In contrast to the short latency to maximal extracellular dopamine, the onset of oral stereotypies was delayed until about 30 min following both routes of drug administration. Furthermore, in contrast to the behavioral response to amphetamine, apomorphine administration resulted in the rapid appearance of oral stereotypies within 5-10 min after drug administration. These results suggest that although caudate-putamen dopamine receptor activation may be a critical factor in the expression of focused oral stereotypies, other effects of amphetamine may interfere with the ability of animals to exhibit these behaviors.


Subject(s)
Amphetamine/administration & dosage , Caudate Nucleus/metabolism , Dopamine Agonists/administration & dosage , Dopamine/metabolism , Putamen/metabolism , Stereotyped Behavior/drug effects , Amphetamine/blood , Amphetamine/pharmacokinetics , Animals , Dopamine Agonists/blood , Dopamine Agonists/pharmacokinetics , Injections, Intravenous , Injections, Subcutaneous , Male , Microdialysis/methods , Rats , Rats, Sprague-Dawley
5.
J Pharmacol Exp Ther ; 288(2): 752-8, 1999 Feb.
Article in English | MEDLINE | ID: mdl-9918585

ABSTRACT

This study evaluated whether the caudate-putamen dopamine response that has been observed after deprenyl administration could be attributed exclusively to metabolically generated l-methamphetamine (l-MeAmp). Brain and plasma levels of deprenyl and l-MeAmp were measured after deprenyl (10 mg/kg s.c.) from 10 to 60 min in conscious rats. Peak caudate-putamen levels were observed for deprenyl (15 nmol/g) at 10 min and for l-MeAmp (3 nmol/g) at 30 min. In a parallel study, l-MeAmp metabolism was evaluated. After l-MeAmp (20 mg/kg s.c.), metabolite levels remained low relative to those of the parent compound: l-amphetamine, approximately 5 to 12%; and para-hydroxy-l-methamphetamine (OH-MeAmp), approximately 0.25%. Accordingly, l-MeAmp was considered to be the primary pharmacologically active deprenyl metabolite. A pharmacokinetic-pharmacodynamic analysis was then used to relate these pharmacokinetic data to the results of previous microdialysis studies in which increases in extracellular dopamine were measured in the caudate-putamen after l-MeAmp (3-18 mg/kg) and after deprenyl (10 mg/kg). Dopamine response-area under curve versus dose plots were generated and used to show that an administered dose of 4 mg/kg l-MeAmp would be necessary to effect a dopamine response-area under curve comparable to that observed after the deprenyl dose. However, the present pharmacokinetic results indicated that l-MeAmp brain levels after deprenyl corresponded to those that would be obtained from 0.4 mg/kg l-MeAmp (i.e., one tenth of the required dose). Collectively, these results suggest that the acute increases in extracellular dopamine observed after deprenyl are not due uniquely to metabolically generated l-MeAmp but also to other actions of deprenyl at the dopamine terminal.


Subject(s)
Antiparkinson Agents/pharmacokinetics , Dopamine Agents/pharmacokinetics , Methamphetamine/pharmacokinetics , Monoamine Oxidase Inhibitors/pharmacokinetics , Selegiline/pharmacokinetics , Animals , Antiparkinson Agents/blood , Antiparkinson Agents/pharmacology , Caudate Nucleus/metabolism , Dopamine Agents/blood , Dopamine Agents/pharmacology , Male , Methamphetamine/blood , Methamphetamine/pharmacology , Monoamine Oxidase Inhibitors/blood , Monoamine Oxidase Inhibitors/pharmacology , Putamen/metabolism , Rats , Rats, Sprague-Dawley , Selegiline/blood , Selegiline/pharmacology
6.
Addict Biol ; 4(3): 283-301, 1999 Jul.
Article in English | MEDLINE | ID: mdl-20575795

ABSTRACT

Studies of most drugs of abuse utilize in vivo animal experimentation so that the responses measured reflect the pharmacokinetics of the administered drug as well as its pharmacodynamics. These drugs are generally lipid soluble chemicals and their elimination is dependent on metabolism, so an understanding of this process is critical to the interpretation of responses. This review summarizes the interaction between drugs of abuse and cytochromes P450, the oxidative enzymes that catalyze the first step of the metabolic process. Although they process their substrates by a common chemical mechanism, these enzymes differ markedly in their regulation, i.e. induction and inhibition, their substrate selectivities, the metabolites they generate and their relative concentration in different species. The activity of an enzyme catalyzing a specific metabolic reaction can be altered by prior xenobiotic exposure, by its genetics and by a co-administered drug, so that the pharmacokinetics of the drug under study can vary with the history of the individual subject. These issues are obviously important in human studies so, when possible, the relevant human enzymes involved in the processes described have been identified.

7.
Drug Metab Dispos ; 25(9): 1059-64, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9311621

ABSTRACT

Methamphetamine (MeAmp) abuse has recently experienced a resurgence and approaches to the treatment of its addiction similar to those used with cocaine have been considered. As the treatment regimes are likely to use drugs whose metabolism is related to that of MeAmp, studies were initiated to establish the enzymology of the fate of MeAmp. This report describes investigations of the role of CYP2D6, the human isoform of the enzyme that catalyzes debrisoquine hydroxylation, in the 4-hydroxylation and N-demethylation of MeAmp. The results of studies with human liver microsomes including those from a genetically poor metabolizer with respect to CYP2D6, showing correlation between MeAmp and metoprolol hydroxylation and MDMA demethylenation, were consistent with a major involvement of CYP2D6 in the aromatic 4-hydroxylation of MeAmp. This was confirmed by studies with recombinant CYP2D6 expressed in yeast, which was also shown to effect the N-demethylation of MeAmp. The rate of the 4-hydroxylation reaction was substantially slower than the demethylenation of MDMA. In contrast to MeAmp, MDMA was not N-demethylated by CYP2D6. Since CYP2D6 participates in the major steps of MeAmp metabolism, pharmacokinetic interactions are likely with other drug substrates proposed for the treatment of MeAmp addiction. Furthermore, the genetic polymorphism associated with the enzyme could manifest itself in abnormal responses to MeAmp.


Subject(s)
Cytochrome P-450 CYP2D6/metabolism , Methamphetamine/metabolism , Microsomes, Liver/metabolism , N-Methyl-3,4-methylenedioxyamphetamine/metabolism , Humans , Oxidation-Reduction , Saccharomyces cerevisiae
8.
J Pharmacol Exp Ther ; 282(2): 591-6, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9262319

ABSTRACT

To further delineate amphetamine-dopamine pharmacokinetic-pharmacodynamic relationships, we examined extracellular levels of dopamine and amphetamine in caudate-putamen after the s.c. administration of 8 mg/kg amphetamine. In a parallel group of animals, we also assessed caudate-putamen tissue levels of the drug. Extracellular concentrations of the transmitter and the drug exhibited similar temporal profiles, each achieving maximum concentrations within 30 min of drug administration. Tissue levels of amphetamine exhibited a similar, although slightly earlier time to maximum levels. The concentrations of amphetamine and dopamine in the extracellular fluid and amphetamine in tissue rapidly declined with similar rates of elimination. In contrast to the temporal profiles for both dopamine and amphetamine, stereotyped behaviors achieved maximum intensity at about 60 min. In addition, although transmitter and drug declined almost 10-fold from maximum values over the 4-hr interval after amphetamine administration, stereotyped behaviors persisted for at least 3 hr before abating. The results of these studies confirm our previous observation that the temporal profiles for stereotyped behaviors and extracellular dopamine are dissociated, and also extend this dissociation to extracellular amphetamine. In addition, although there was a close correspondence between dopamine and amphetamine within each experimental animal, individual animals exhibited a broad range of maximal dopamine responses, suggesting a differential responsiveness to amphetamine.


Subject(s)
Amphetamine/administration & dosage , Amphetamine/metabolism , Behavior, Animal/drug effects , Caudate Nucleus/drug effects , Dopamine/metabolism , Putamen/drug effects , Amphetamine/pharmacology , Animals , Caudate Nucleus/metabolism , Dialysis , Extracellular Space/metabolism , Putamen/metabolism , Rats
9.
Xenobiotica ; 27(4): 379-87, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9149377

ABSTRACT

1. The cytochrome P450 isozymes involved in the deamination of amphetamine (AP) and benzphetamine (BZP) have been studied in liver microsomes from rabbit and rat using isozyme-specific inhibitors. 2. Metabolism of BZP in rat yielding phenylacetone and formaldehyde was moderately inhibited by testosterone and chloramphenicol. N-Debenzylation was thought to be P450-dependent, but all inhibitors except for a non-specific inhibitor, SKF-525A, failed to inhibit this reaction. 3. In rabbit, quinidine and testosterone were potent inhibitors of both BZP deamination and dealkylation. Deamination of AP in rabbit was extensively inhibited only with quinidine. 4. AP deamination with purified rabbit CYP2C3, which was previously identified as the major isozyme responsible for this metabolism, was extensively inhibited with quinidine, previously thought to be a specific inhibitor of CYP2D. 5. These results strongly support the notion that the CYP2C isozymes play a major role in the deamination of both AP and BZP, but not for N-debenzylation of BZP in rat. However, on the basis of different sensitivities toward inhibitors, multiple isozymes seem to be involved in BZP deaminations in both species.


Subject(s)
Amphetamine/pharmacokinetics , Aryl Hydrocarbon Hydroxylases , Benzphetamine/pharmacokinetics , Central Nervous System Stimulants/pharmacokinetics , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Isoenzymes/antagonists & inhibitors , Quinidine/pharmacology , Steroid 16-alpha-Hydroxylase , Animals , Cytochrome P-450 Enzyme System/metabolism , Dealkylation , Deamination , In Vitro Techniques , Isoenzymes/metabolism , Male , Microsomes, Liver/enzymology , Rabbits , Rats , Rats, Sprague-Dawley , Species Specificity , Stereoisomerism , Steroid Hydroxylases/antagonists & inhibitors , Steroid Hydroxylases/metabolism , Substrate Specificity
10.
Chem Res Toxicol ; 10(3): 289-95, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9084908

ABSTRACT

Repeated administration of propranolol (PL) to rats causes the inhibition of cytochrome P450-2D (P450-2D) enzyme. We recently found that 4-hydroxypropranolol (4-OH-PL) was biotransformed to 1,4-naphthoquinone (1,4-NQ) by superoxide (SO) anions in medium containing rat liver microsomes and NADPH and proposed that the binding of the quinone to P450-2D apoproteins might be one of mechanisms for the enzyme inhibition [Narimatsu et al. (1995) Chem. Res. Toxicol. 8, 721-728]. In this study, we have searched for possible sources of SO for the conversion of 4-OH-PL to 1,4-NQ in rat liver microsomes and determined the radioactivity covalently bound to microsomal proteins after incubation of radioactive PL and 4-OH-PL with rat liver microsomes. Elimination of 4-OH-PL from a mixture containing microsomes and NADPH was suppressed by carbon monoxide. Antibodies raised to P450-2B1 and -3A2 partially, and antibody against NADPH-cytochrome P450 reductase (fp2) markedly suppressed the reaction. 1,4-NQ was formed concomitantly with 4-OH-PL elimination by a reconstituted preparation of fp2. Binding studies using naphthalene ring (NR)- and side chain (SC)-radiolabeled PL and 4-OH-PL showed that radioactivity covalently bound to microsomal proteins was much higher from 4-OH-PL than from PL for the NR-labeled compounds, but higher from PL than from 4-OH-PL for the SC-labeled compounds. These results suggest that the 4-OH-PL formed from PL by P450-2D enzyme is converted to 1,4-NQ with loss of the side chain, and the 1,4-NQ accounts for most of the radioactivity covalently bound to microsomal proteins, including the P450-2D enzymes. The SO for conversion of 4-OH-PL to 1,4-NQ is supplied mainly by fp2 with some contribution by P450 enzymes.


Subject(s)
Adrenergic beta-Antagonists/metabolism , Microsomes, Liver/metabolism , Propranolol/analogs & derivatives , Animals , Biotransformation , Carbon Monoxide/pharmacology , Cytochrome P-450 Enzyme System/biosynthesis , Cytochrome P-450 Enzyme System/immunology , Enzyme Induction/drug effects , Female , In Vitro Techniques , Male , Naphthalenes/chemistry , Phenobarbital/pharmacology , Propranolol/metabolism , Protein Binding , Rabbits , Rats , Superoxides/metabolism
11.
J Toxicol Sci ; 22(1): 65-73, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9076658

ABSTRACT

Deamination or oxidative cleavage of the carbon-nitrogen bond in various phenylisopropylamines was examined in liver microsomes from rabbits and rats, and in reconstituted systems containing CYP2C subfamily isozymes. Kinetic studies of phenylacetone formation from six amphetamine (AP) derivatives, catalyzed by rabbit liver microsomes, indicated that AP had the highest apparent affinity (lowest K(m)) and increasing the size of the substituent on the nitrogen atom decreased the affinity. The values of maximal velocity increased with increasing size of the substituent. Experiments with purified CYP2C3 from rabbit liver gave similar results: this enzyme showed the highest activity for phenylacetone formation from benzphetamine (BZP) and showed lower activities with compounds having smaller nitrogen substituents. Based on these results, we conclude that among a series of AP derivatives, the parent phenylisopropylamine has the highest affinity for rabbit liver deaminase, where as BZP has the highest turnover. However, the intrinsic clearance (Vmax/K(m)) values for the individual reactions tended to be comparable. The rates of BZP and deprenyl N-demethylation by rat CYP2C11 and 2C13 were far greater than those of the reactions at other N-alpha-positions. This result indicated that rat CYP2C enzymes have a more rigid regioselectivity than rabbit CYP2C3 for the deamination/N-dealkylation of phenylisopropylamines.


Subject(s)
Amphetamines/metabolism , Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 Enzyme System/pharmacology , Isoenzymes/pharmacology , Microsomes, Liver/enzymology , Steroid 16-alpha-Hydroxylase , Steroid Hydroxylases/pharmacology , Animals , Catalysis , Cytochrome P-450 Enzyme System/isolation & purification , Cytochrome P450 Family 2 , Deamination/drug effects , Isoenzymes/isolation & purification , Male , Rabbits , Rats , Rats, Sprague-Dawley , Steroid Hydroxylases/isolation & purification , Structure-Activity Relationship , Substrate Specificity/drug effects
12.
Chem Biol Interact ; 101(3): 207-24, 1996 Sep 06.
Article in English | MEDLINE | ID: mdl-8870689

ABSTRACT

Repeated oral administration of propranolol (PL, 100 mg/kg daily, for 5, 10 and 15 days) to male Wistar rats increased PL N-desisopropylase and decreased PL 4-,5- and 7-hydroxylase activities in liver microsomes. The increase was highest at the 10 day time point whereas the decrease was relatively constant over the 15 day treatment period. There were no significant changes in the total content of cytochromes P450 (P450) or cytochrome b5 or in NADPH-cytochrome c reductase activity during the PI, treatment. The enhanced N-desisopropylase activities were markedly inhibited by alpha-naphthoflavone (a P450-1A1/2 inhibitor), and moderately by triacetyloleandomycin (a P450-3A1/2 inhibitor) and diethyldithiocarbamate (a P450-2E1 inhibitor). Phenacetin O-deethylase activity, an index of P450-1A2, was significantly increased on day 5, 10 and 15 of the treatment, whereas p-nitrophenol hydroxylase activity was elevated on day 10 only. The PL N-desisopropylation showed a strong and significant correlation with phenacetin O-deethylation, and a weaker but significant correlation with p-nitrophenol hydroxylation. Immunoblot analysis revealed that a protein band corresponding to P450-1A2 was increased by PL pretreatment, and protein band corresponding to P450-3A tended to be increased slightly, but other protein band corresponding to the subfamily of P450-2B, -2C, or -2E was not changed. Pretreatment of rats with P450 inducers (beta-naphthoflavone, phenobarbital, acetone and dexamethasone) increased PL N-dealkylase activity in liver microsomes. Furthermore, antibodies raised against P450-1A and -3A enzymes suppressed PL N-desisopropylation in a concentration-dependent manner, but P450-2E antibody did not. Reconstitution studies showed that P450-1A1, -1A2, -2E1 and -3A2 exhibited catalytic activities for PL N-dealkylation. These results suggest that P450-1A2 is a major PL N-desisopropylase in the PL-treated rats, and P450-3A related enzyme(s) and P450-2E1 as a moderate or minor enzyme are also involved in PL N-dealkylation in native and PL-treated rats.


Subject(s)
Adrenergic beta-Antagonists/metabolism , Cytochrome P-450 Enzyme System/metabolism , Isoenzymes/metabolism , Microsomes, Liver/enzymology , Propranolol/metabolism , Administration, Oral , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/pharmacology , Animals , Benzoflavones/pharmacology , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/chemistry , Electrophoresis, Polyacrylamide Gel , Enzyme Induction/drug effects , Enzyme Inhibitors/pharmacology , Hydroxylation , Immunoblotting , Isoenzymes/antagonists & inhibitors , Isoenzymes/chemistry , Male , Microsomes, Liver/drug effects , Propranolol/administration & dosage , Propranolol/pharmacology , Rats , Rats, Wistar , Troleandomycin/pharmacology
13.
J Pharmacol Exp Ther ; 277(2): 595-603, 1996 May.
Article in English | MEDLINE | ID: mdl-8627536

ABSTRACT

The high selectivity of amphetamine and its derivatives for CYP2D-mediated oxidations suggested the use of the phenylisopropylamine skeleton as a template for a selective inhibitor of this important enzyme. Accordingly, 4-allyloxymethamphetamine-amine (ALLMA) was synthesized and its ability to selectively inactivate CYP2D was investigated both in in vitro and in vivo experiments. Incubation studies with rat liver microsomes demonstrated that this compound suppressed the CYP2D-mediated methylenedioxymethamphetamine (MDMA) demethylation in time- and dose-dependent manner and that the inhibition required the presence of NADPH. The development of irreversible inhibition was associated with oxidation at position 4 of the aromatic ring, the common site of CYP2D-mediated oxidation of this group of compounds. In in vivo studies doses of ALLMA (1-10 mg/kg) were administered to adult male Sprague-Dawley rats and liver microsomes were obtained 3 hr later. Methamphetamine p-hydroxylation and low Km MDMA demethylation activities, both mediated by CYP2D, were reduced by more than 80% after a dose of 10 mg/kg. Cytochrome P-450 reactions attributed to P-450s other than CYP2D, such as aniline p-hydroxylation, the high Km system of MDMA demethylation and the N-demethylation of methamphetamine, benzphetamine, aminopyrine and erythromycin, all appeared to be minimally affected. The importance of aromatic ring oxidation in the metabolism is such that inhibition of CYP2D would be expected to cause a significant change in the pharmacokinetics of these compounds. The kinetics of MDMA metabolic activity in microsomes from ALLMA-pretreated rats were comparable to those from female Dark-Agouti rats, an animal model for CYP2D1 deficiency.


Subject(s)
Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Methamphetamine/analogs & derivatives , Animals , Dealkylation , Dose-Response Relationship, Drug , Ethanolamines/pharmacology , Female , Male , Methamphetamine/pharmacology , Phencyclidine/pharmacology , Propranolol/pharmacology , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
14.
Biochem Pharmacol ; 51(6): 789-96, 1996 Mar 22.
Article in English | MEDLINE | ID: mdl-8602874

ABSTRACT

3,4-Methylenedioxymethamphetamine (MDMA) affects both dopamine and serotonin (5-HT) systems. One of its acute actions is to cause a reversible fall in steady-state brain 5-HT concentrations. To investigate the chemical basis of this acute effect, the brain levels of the parent compound and three major metabolites, 3,4- 3,4-methylenedioxyamphetamine (MDA), 3,4-dihydroxymethamphetamine (DHMA) and 6-hydroxy-3,4-methylenedioxymethamphetamine (6-OHMDMA), were monitored, together with 5-HT levels, over a period of 6 hr in male Sprague-Dawley (SD) rats. The temporal relationships between drug concentrations of both stereoisomers and depletions were evaluated first. There was no correlation between the concentrations of the compounds measured and the extent of 5-HT depletion. Brain levels of MDMA and MDA were higher than plasma levels and exhibited a stereoselectivity in that (-)-MDMA and (+)-MDA levels were higher than those of enantiomers. The relationship between the dose of ((+)-MDMA and reduction in 5-HT levels was next investigated in SD male, SD female, and Dark Agouti (DA) female rats. These animals exhibit different capabilities of MDMA metabolism. There is a lower level of MDA, the N-demethylated metabolite of MDMA, in female SD rats than in males. Female DA rats are deficient in CYP2D isozymes, one of the enzymes responsible for demethylenation of MDMA to DHMA at pharmacological concentrations of substrate. there was a significant accuulation of MDMA in the brain and plasma of DA rats, but their 5-HT depletion was somewhat attenuated. The results indicated that MDMA ++ was apparently not the single, causative agent for the acute 5-HT depletion, which may also involve a metabolite formed by CYP2D.


Subject(s)
Brain/drug effects , Brain/metabolism , Hallucinogens/pharmacology , Hallucinogens/pharmacokinetics , N-Methyl-3,4-methylenedioxyamphetamine/pharmacology , N-Methyl-3,4-methylenedioxyamphetamine/pharmacokinetics , Serotonin/metabolism , 3,4-Methylenedioxyamphetamine/analogs & derivatives , 3,4-Methylenedioxyamphetamine/metabolism , Animals , Dose-Response Relationship, Drug , Female , Hallucinogens/metabolism , Male , Methylation , N-Methyl-3,4-methylenedioxyamphetamine/metabolism , Rats , Rats, Inbred Strains , Rats, Sprague-Dawley , Sex Factors , Species Specificity , Stereoisomerism
15.
Chem Res Toxicol ; 8(5): 721-8, 1995.
Article in English | MEDLINE | ID: mdl-7548755

ABSTRACT

We have characterized a chemically reactive propranolol (PL) metabolite which binds to proteins in rat liver microsomes. During incubation with rat liver microsomes (1 mg of protein) fortified with an NADPH-generating system, 4-hydroxypropranolol (4-OH-PL) quickly disappeared from the reaction medium, but none of the possible metabolite peaks was detected under the high-performance liquid chromatographic conditions used. The consumption of 4-OH-PL depended on microsomes and NADPH. The reaction was not affected by inhibitors of cytochrome P450 or FAD monooxygenase, but was markedly diminished in the presence of cytosol and ascorbic acid. The effect of cytosol was inhibited by potassium cyanide but not by sodium benzoate or dimethyl sulfoxide, and was also not affected by heating at 60 degrees C for 30 min, suggesting that superoxide (SO) ion was involved in the reaction and that it was blocked by superoxide dismutase (SOD) present in the cytosol. Cu,Zn-SOD, purified from cytosol, effectively mimicked the suppressive effect of cytosol. Incubation of 4-OH-PL in an SO-generating system of xanthine and xanthine oxidase generated 1,4-naphthoquinone (1,4-NQ), which was identified by TLC, HPLC, and GC/MS. 1,4-NQ was also formed in microsomal incubates containing NADPH and small amounts of microsomes (below 0.1 mg of protein). These results indicate that 4-OH-PL is converted by SO, or some reactive oxygen species derived from it, to 1,4-NQ which binds to proteins and is one of the reactive metabolites of PL.


Subject(s)
Microsomes, Liver/metabolism , Propranolol/analogs & derivatives , Animals , Biotransformation , Kinetics , Male , Naphthoquinones/metabolism , Propranolol/metabolism , Protein Binding , Rats , Rats, Wistar , Spectrum Analysis , Superoxide Dismutase/metabolism , Superoxides/metabolism , Xanthine Oxidase/metabolism , Xanthines/metabolism
16.
J Pharmacol Exp Ther ; 274(1): 90-6, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7616454

ABSTRACT

To establish whether the actions of D-amphetamine (Amp) and D-methamphetamine (MeAmp) on the striatal dopamine system were equipotent, pharmacokinetic profiles of each drug were applied to an analysis of their respective induced dopamine efflux profiles. Amp or MeAmp (1 and 5 mg/kg i.v.) was administered to chloral hydrate-anesthetized rats; plasma and brain kinetics were then assessed from 5 to 60 min. Dose-dependent increases in Amp and MeAmp plasma levels resulted in proportional increases in striatum levels that were equivalent for both drugs; elimination rates also were similar and were characterized by a first-order decay process. After MeAmp administration, low levels of brain MeAmp metabolites were detected throughout the 1-hr time period; relative to MeAmp, Amp and p-hydroxy-MeAmp levels were less than 10 and 1%, respectively. The drug-induced dopamine efflux profiles in the striatum were characterized by microdialysis; Amp and MeAmp (1, 2.5 and 5 mg/kg i.v.) effected equivalent, dose-dependent increases in extracellular dopamine levels. For both drugs at 5- and 10-min postinjection, increases in drug striatum levels preceded increases in dopamine efflux. In contrast, from the time of the peak dopamine responses observed at 10 to 20 min until the end of the study at 90 min, changes in striatal drug levels were correlated with extracellular dopamine levels; this correlation was similar for both drugs. These results indicate that Amp and MeAmp pharmacokinetics and their subsequent dopamine responses in the striatum are equivalent. The pharmacokinetic analysis can be extended to the interpretation of other comparative studies that assess effects of Amp and MeAmp.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Corpus Striatum/drug effects , Dextroamphetamine/pharmacology , Dopamine/metabolism , Methamphetamine/pharmacology , Animals , Corpus Striatum/metabolism , Dextroamphetamine/blood , Dextroamphetamine/pharmacokinetics , Male , Methamphetamine/blood , Methamphetamine/pharmacokinetics , Rats , Rats, Sprague-Dawley
17.
Drug Metab Dispos ; 23(6): 610-4, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7587941

ABSTRACT

The 4-hydroxylation of S(+)- and R(-)-methamphetamine by rat liver microsomes was examined in Sprague-Dawley and Dark Agouti strains to determine the role of cytochrome P4502D (CYP2D) subfamily isozymes in catalyzing the reaction. In the study, anti-P450-BTL IgG, bufuralol, and quinine, a substrate and inhibitors of CYP2D isozymes, respectively, were found to block approximately 90% of the reaction as catalyzed by microsomes from Sprague-Dawley rats. Reconstituted systems of CYP2D isozymes purified from rat liver microsomes also mediated the reaction. These observations and the minimal activity found in microsomes from Dark Agouti rats support the notion that methamphetamine, like other phenylisopropylamine compounds, is oxidized on the 4-position of the aromatic ring by CYP2D isozymes.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Isoenzymes/metabolism , Methamphetamine/metabolism , Animals , Catalysis , Humans , Hydroxylation , Kinetics , Male , Microsomes, Liver/enzymology , Rats , Rats, Sprague-Dawley , Sex Factors , Stereoisomerism
18.
J Neurosci ; 15(2): 1308-17, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7869099

ABSTRACT

Microdialysis in behaving animals was used to concomitantly characterize the dopamine and 5-HT responses in the caudate and the norepinephrine response in the hippocampus to the D- and L-isomers of amphetamine and methamphetamine. Doses of all four drugs which promoted similar stereotypy responses produced a D-amphetamine-like response profile of dopamine and dopamine metabolites, suggesting that all these drugs interact with dopamine systems to facilitate the release of transmitter. However, in contrast to the similar behavioral profiles, the magnitude of the dopamine responses diverged significantly. In addition, all four drugs increased extracellular norepinephrine and 5-HT, but the relative responses differed markedly from dopamine and from each other. The contrasting structure-activity relationships for these drugs likely reflect their differential potency at the various neuronal uptake transporters in promoting either transmitter release, and/or uptake blockade. In addition, the interaction of each drug at the vesicular transporters, as well as the availability of a cytoplasmic pool of transmitter likely also contribute to the neurotransmitter response. Because of the particularly divergent transmitter response profiles exhibited by L-methamphetamine, its behavioral and neurotransmitter effects were characterized over a more extended range of doses. Although the duration of the increase in extracellular dopamine was clearly proportional to dose, the dose-dependent increases in the magnitude of the dopamine response did not parallel the behavioral profiles. The results of these studies indicate that, while the dopamine, norepinephrine and 5-HT responses to these drugs probably contribute to the expression of stimulant-induced behaviors, simple relationships between the neurotransmitter responses and the behavioral profiles were not evident.


Subject(s)
Amphetamine/pharmacology , Behavior, Animal/drug effects , Caudate Nucleus/metabolism , Hippocampus/metabolism , Methamphetamine/pharmacology , Neurotransmitter Agents/metabolism , Animals , Dopamine/metabolism , Microdialysis , Norepinephrine/metabolism , Rats , Serotonin/metabolism , Stereoisomerism , Stereotyped Behavior/drug effects
19.
Drug Metab Dispos ; 23(2): 201-6, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7736912

ABSTRACT

The purpose of this study was to determine whether phencyclidine (PCP) inhibits constitutive hepatic cytochrome P450 (CYP) isozymes when administered to naive adult male Sprague-Dawley rats. Animals were pretreated with PCP (25 mg/kg/day for 2 days), killed 3 and 16 hr after the last dose, and liver microsomes prepared. The washed microsomes were then assayed for benzphetamine, methamphetamine (MA), and methylenedioxymethamphetamine (MDMA) N-demethylation together with MDMA demethylenation and MA 4-hydroxylation activities. MDMA demethylenation (low substrate concentration), MA 4-hydroxylation, and metoprolol alpha-hydroxylation reactions, which are catalyzed by CYP2D isozymes, were reduced > 74% 3 hr after the last PCP dose and were only partially restored 13 hr later. Benzphetamine and (-)-MDMA N-demethylation activities were restored to control values 16 hr after the last dose. These results indicate that PCP suppresses constitutive isozymes, including CYP2C11 and members of the CYP2D subfamily. The suppression of cytochromes P450 activity by PCP in vivo is consistent with its in vitro actions found in this and other studies, and demonstrates that alteration of CYP activity is another pharmacological effect of this compound.


Subject(s)
Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/metabolism , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Liver/drug effects , Liver/enzymology , Phencyclidine/pharmacology , Amphetamines/pharmacokinetics , Animals , Biotransformation , Cyanides/pharmacology , Cytochrome P-450 Enzyme System/drug effects , Drug Interactions , Enzyme Activation , Isoenzymes/drug effects , Male , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Rats , Rats, Sprague-Dawley
20.
Biochem Pharmacol ; 47(7): 1151-6, 1994 Mar 29.
Article in English | MEDLINE | ID: mdl-7909223

ABSTRACT

The metabolism of methylenedioxymethamphetamine (MDMA, "ecstasy") was examined in a microsomal preparation of the yeast Saccharomyces cerevisiae expressing human debrisoquine hydroxylase, CYP2D6. Only one product, dihydroxymethylamphetamine (DHMA), was detected in the incubation mixture, and this product accounted for all of the substrate consumption at low concentration (10 microM). Mean +/- SD values of apparent Km(microM) and Vmax (nmol/min per nmol P450) for the demethylenation of (+) and (-)-MDMA at low concentrations (1-100 microM) were 1.72, 0.12 and 6.45, 0.10 and 2.90, 0.10 and 7.61, 0.06, respectively. At high concentrations (> 1000 microM) substrate inhibition was noted, with Ki values of 14.2 and 28.2 mM, respectively, for the (+) and (-) enantiomers. Incubation of MDMA isomers with human liver microsomes indicated that their demethylenation is deficient in the poor metabolizer phenotype. Thus, MDMA is converted to the catecholamine DHMA by CYP2D6, and this may give rise to genetically-determined differences in toxicity.


Subject(s)
3,4-Methylenedioxyamphetamine/analogs & derivatives , Cytochrome P-450 Enzyme System/metabolism , Microsomes, Liver/enzymology , Mixed Function Oxygenases/metabolism , 3,4-Methylenedioxyamphetamine/metabolism , Cytochrome P-450 CYP2D6 , Cytochrome P-450 Enzyme System/genetics , Deoxyepinephrine/analogs & derivatives , Deoxyepinephrine/analysis , Humans , Kinetics , Male , Middle Aged , Mixed Function Oxygenases/genetics , N-Methyl-3,4-methylenedioxyamphetamine , NADP/metabolism , Saccharomyces cerevisiae/enzymology , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...